TN2009000486A1 - Raf inhibitors for the treatment of thyroid cancer - Google Patents

Raf inhibitors for the treatment of thyroid cancer

Info

Publication number
TN2009000486A1
TN2009000486A1 TNP2009000486A TN2009000486A TN2009000486A1 TN 2009000486 A1 TN2009000486 A1 TN 2009000486A1 TN P2009000486 A TNP2009000486 A TN P2009000486A TN 2009000486 A TN2009000486 A TN 2009000486A TN 2009000486 A1 TN2009000486 A1 TN 2009000486A1
Authority
TN
Tunisia
Prior art keywords
thyroid cancer
treatment
specifically
raf inhibitor
ptc
Prior art date
Application number
TNP2009000486A
Other languages
English (en)
Inventor
Darrin Douglas Stuart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39749309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000486A1 publication Critical patent/TN2009000486A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TNP2009000486A 2007-05-23 2009-11-20 Raf inhibitors for the treatment of thyroid cancer TN2009000486A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93962507P 2007-05-23 2007-05-23
PCT/US2008/064280 WO2008147782A1 (fr) 2007-05-23 2008-05-21 Inhibiteurs de raf pour le traitement du cancer de la thyroïde

Publications (1)

Publication Number Publication Date
TN2009000486A1 true TN2009000486A1 (en) 2011-03-31

Family

ID=39749309

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000486A TN2009000486A1 (en) 2007-05-23 2009-11-20 Raf inhibitors for the treatment of thyroid cancer

Country Status (18)

Country Link
US (2) US20100160381A1 (fr)
EP (1) EP2150252A1 (fr)
JP (1) JP2010528032A (fr)
KR (1) KR20100017894A (fr)
CN (1) CN101674828A (fr)
AU (1) AU2008256922B2 (fr)
BR (1) BRPI0811097A2 (fr)
CA (1) CA2686787A1 (fr)
CL (1) CL2008001492A1 (fr)
IL (1) IL201690A0 (fr)
MA (1) MA31446B1 (fr)
MX (1) MX2009012626A (fr)
NZ (1) NZ580592A (fr)
RU (1) RU2009147291A (fr)
TN (1) TN2009000486A1 (fr)
TW (1) TW200914008A (fr)
WO (1) WO2008147782A1 (fr)
ZA (1) ZA200907250B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
WO2017136741A1 (fr) * 2016-02-05 2017-08-10 Evol Science LLC Combinaisons pour le traitement du cancer
AU2018313111A1 (en) * 2017-08-07 2020-03-19 Evol Science LLC Combinations to treat cancer
BR112021013637A2 (pt) 2019-01-11 2021-09-14 Naegis Pharmaceuticals Inc. Inibidores da síntese de leucotrieno

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7423150B2 (en) * 2003-10-16 2008-09-09 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of Raf kinase
PE20070335A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
BRPI0808526A2 (pt) * 2007-03-02 2014-08-19 Novartis Ag Formas sólidas de um inibidor de raf cinase

Also Published As

Publication number Publication date
ZA200907250B (en) 2010-07-28
WO2008147782A1 (fr) 2008-12-04
KR20100017894A (ko) 2010-02-16
AU2008256922A1 (en) 2008-12-04
MA31446B1 (fr) 2010-06-01
AU2008256922B2 (en) 2011-07-28
CA2686787A1 (fr) 2008-12-04
IL201690A0 (en) 2010-05-31
RU2009147291A (ru) 2011-06-27
CN101674828A (zh) 2010-03-17
EP2150252A1 (fr) 2010-02-10
TW200914008A (en) 2009-04-01
JP2010528032A (ja) 2010-08-19
MX2009012626A (es) 2009-12-07
US20100160381A1 (en) 2010-06-24
CL2008001492A1 (es) 2009-02-20
US20120213867A1 (en) 2012-08-23
NZ580592A (en) 2012-02-24
BRPI0811097A2 (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
EA201270184A1 (ru) Лечение расстройств печени ингибиторами pi3k
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
MX2009005649A (es) Tratamiento para mieloma multiple.
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA201690033A3 (ru) Морфинановые соединения
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201290919A1 (ru) Индазольные соединения и их применение
MX2007009649A (es) Derivados de meleimida, composiciones farmaceuticas y metodos para el tratamiento del cancer.
EA201890768A2 (ru) Лечение злокачественной опухоли ингибиторами tor-киназы
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
JO2848B1 (en) Organic compounds
MA32907B1 (fr) Régime posologique d'un agoniste du récepteur s1p
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2008040548A3 (fr) Traitement pour l'hépatite stéatosique non alcoolique
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
GT200600160A (es) Tratamiento del dolor
CY1115081T1 (el) Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του
EA201170425A1 (ru) Тетрациклиновые соединения для лечения ревматоидного артрита и связанные с ними способы лечения
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
EA201001496A1 (ru) Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
TN2009000486A1 (en) Raf inhibitors for the treatment of thyroid cancer
WO2008073466A3 (fr) Alpha b-cristalline en tant que traitement de l'inflammation